Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.